July 28, 2020 10:37 AM EDTUpdated 10:47 AM
R&D

Af­ter stop­ping Farx­i­ga tri­al ear­ly, As­traZeneca de­clares suc­cess in CKD treat­ment

Max Gelman

Senior Editor

Back in March, As­traZeneca an­nounced plans to halt a Phase III tri­al for its Farx­i­ga drug ahead of sched­ule af­ter see­ing “over­whelm­ing ef­fi­ca­cy” in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Im­munol­o­gy biotech In­ma­gene to join Nas­daq through re­verse merg­er with what's left of Ike­na

A service from the Financial Times